Optimer Partners with Astellas Again to Commercialise Fidaxomicin in Japan
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 4 (Table of Contents)
Published: 9 Apr-2012
DOI: 10.3833/pdr.v2012.i4.1711 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Optimer Pharmaceuticals and Astellas Pharma have teamed up again for the development and commercialisation of fidaxomicin, Optimer’s twice-daily antibiotic for Clostridium difficile infection, this time in Japan...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS